...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Determination of the International Sensitivity Index of a new near-patient testing device to monitor oral anticoagulant therapy--overview of the assessment of conformity to the calibration model.
【24h】

Determination of the International Sensitivity Index of a new near-patient testing device to monitor oral anticoagulant therapy--overview of the assessment of conformity to the calibration model.

机译:确定用于监测口服抗凝治疗的新型近距离患者测试设备的国际敏感性指数-评估与校准模型的一致性

获取原文
获取原文并翻译 | 示例
           

摘要

A key issue for the reliable use of new devices for the laboratory control of oral anticoagulant therapy with the INR is their conformity to the calibration model. In the past, their adequacy has mostly been assessed empirically without reference to the calibration model and the use of International Reference Preparations (IRP) for thromboplastin. In this study we reviewed the requirements to be fulfilled and applied them to the calibration of a new near-patient testing device (TAS, Cardiovascular Diagnostics) which uses thromboplastin-containing test cards for determination of the INR. On each of 10 working days citrated whole blood and plasma samples were obtained from 2 healthy subjects and 6 patients on oral anticoagulants. PT testing on whole blood and plasma was done with the TAS and parallel testing for plasma by the manual technique with the IRP CRM 149S. Conformity to the calibration model was judged satisfactory if the following requirements were met: (i) there was a linear relationship between paired log-PTs (TAS vs CRM 149S); (ii) the regression line drawn through patients data points, passed through those of normals; (iii) the precision of the calibration expressed as the CV of the slope was <3%. A good linear relationship was observed for calibration plots for plasma and whole blood (r = 0.98). Regression lines drawn through patients data points, passed through those of normals. The CVs of the slope were in both cases 2.2% and the ISIs were 0.965 and 1.000 for whole blood and plasma. In conclusion, our study shows that near-patient testing devices can be considered reliable tools to measure INR in patients on oral anticoagulants and provides guidelines for their evaluation.
机译:对于使用INR进行口服抗凝治疗的实验室控制,要可靠地使用新设备进行实验室控制,关键问题在于它们是否符合校准模型。过去,它们的适用性大多是通过经验评估的,而没有参考校准模型和凝血酶原的国际参考制剂(IRP)的使用。在这项研究中,我们审查了要满足的要求,并将其应用于新的近端测试设备(TAS,心血管诊断)的校准,该设备使用含促凝血酶原蛋白的测试卡确定INR。在10个工作日的每一天,从2名健康受试者和6名口服抗凝剂患者中获取柠檬酸全血和血浆样品。使用TAS对全血和血浆进行PT测试,并通过IRP CRM 149S手动技术对血浆进行并行测试。如果满足以下要求,则认为与校准模型的符合性令人满意:(i)配对log-PT之间存在线性关系(TAS与CRM 149S); (ii)通过患者数据点绘制的回归线,穿过正常值; (iii)以斜率CV表示的校准精度<3%。在血浆和全血的校准图上观察到良好的线性关系(r = 0.98)。通过患者数据点绘制的回归线穿过法线。在两种情况下,全血和血浆的斜率CV均为2.2%,ISI为0.965和1.000。总之,我们的研究表明,可以将近患者测试设备视为测量口服抗凝剂患者INR的可靠工具,并为其评估提供指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号